Challenges in implementing universal lung cancer biomarker testing

Matthew Smeltzer, PhD, University of Memphis, Memphis, TN, comments on barriers to widespread biomarker testing for lung cancer. Clinicians may have reservations in terms of the cost to benefit ratio and more education is recommended for them, especially if they have not been updated on novel techniques such as next-generation sequencing (NGS). Dr Smeltzer additionally highlights the need to implement policies that make biomarker testing more affordable for healthcare providers and other related stakeholders. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.